Background Canada’s youth are facing mental health crises due to barriers in accessing timely and affordable care. Ontario’s OHIP+ pharmacare program, introduced in 2018, provided free prescription drug coverage to individuals under 25. While OHIP+ increased prescription use, its effects on perceived access and well-being among youth with mental health needs remain unclear.

Methods We used a regression discontinuity design leveraging the OHIP+ age-eligibility cutoff at 25 to estimate its causal impact on unmet health care needs and self-perceived life stress. The sample included Ontario respondents aged 20–29 (n=1,053) from the 2018–2019 Canadian Community Health Survey who reported needing mental health support. Outcomes were self-reported unmet health care needs and a 5-point life stress scale. Models adjusted for sociodemographic factors and used age in months as the running variable.

Results Loss of OHIP+ eligibility at age 25 was associated with a 19.0 percentage-point increase in the probability of reporting unmet health care needs (95% CI: 0.5 to 37.6 percentage points) and a 1.33-point increase in perceived life stress (95% CI: 0.45 to 2.21). These effects were consistent across subgroups and robust to multiple sensitivity tests.

Conclusion OHIP+ improved access and reduced stress among youth with mental health needs while coverage was in place. However, the abrupt loss of eligibility at age 25 increased unmet needs and psychological strain, underscoring the need for continuous, inclusive pharmacare to support youth well-being.

What is already known on this topic Public drug coverage programs such as OHIP+ have been shown to increase prescription drug use among youth in Ontario, Canada. However, little is known about whether such programs improve patient-perceived outcomes. Existing evaluations have largely relied on descriptive data or aggregate prescribing trends, with few studies examining individual-level outcomes using quasi-experimental methods.

What this study adds Using a regression discontinuity design, this study provides the causal evidence that the OHIP+ pharmacare program reduced unmet health care needs and life stress among youth with perceived mental health concerns while they remained eligible for coverage. The findings show that the abrupt loss of eligibility at age 25 was associated with increased unmet needs and heightened stress, suggesting that age-based cutoffs in drug coverage may disrupt care and contribute to psychological strain during a critical life stage.

How this study might affect research, practice or policy This study suggests that universal drug coverage programs should ensure continuity through young adulthood to avoid worsening access gaps. The findings support the need for a national pharmacare framework that promotes equitable and sustained health support.

The authors have declared no competing interest.

This project was funded by the Canadian Institutes of Health Research (Project Grant FRN# 525784, NPI: Antony Chum). The project principal investigator (Antony Chum) is supported by the Canada Research Chair Program (grant CRC-2021-00269). This project is also supported by the Karen Maxwell Foundation (no grant number applicable).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

This study utilized de-identified microdata accessed through the Research Data Centre (RDC) program managed by Statistics Canada. The data are protected by strict confidentiality provisions under the Statistics Act and are accessible only to researchers with approved projects who meet security and confidentiality requirements. The data are not publicly available but can be accessed upon request to Statistics Canada through their RDC program, subject to similar security, confidentiality, and ethical requirements.